Live Breaking News & Updates on Pegylated interferon

Stay informed with the latest breaking news from Pegylated interferon on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pegylated interferon and stay connected to the pulse of your community

Phase 3 Trial Reports Promising Results for New COVID Treatment

'The data look quite promising and other treatments have now fallen by the wayside,' said Paul Sax, MD, of Brigham and Women's Hospital in Boston.

New-york , United-states , Boston , Massachusetts , Canada , Toronto , Ontario , Brazil , American , Paul-sax , University-of-toronto , New-york-times

Bulevirtide Reduces Hepatitis D Viral Load

Data from an ongoing study in patients with compensated cirrhosis and clinically significant portal hypertension have raised hope for an emerging treatment option in this rare, deadly disease.

Italy , Milan , Lombardia , United-states , France , Maggiore-policlinico , Bulevirtide-hepcludex , Marc-bourli , International-liver-congress , Elisabetta-degasperi , Grand-hospital-maggiore-policlinico , Unmet-therapeutic

Zydus Cadila Q4 net profit up 73 pc at Rs 679 crore

Ahmedabad (Gujarat) [India], May 27 (ANI): Pharmaceutical major Zydus Cadila said on Thursday its net profit jumped 73 per cent year-on-year to Rs 679 crore during the quarter ended March.

Ahmedabad , Gujarat , India , Zydus-cadila , Drug-administration , Pegylated-interferon , Et-profit , Bitda , Otal-income-from-operations , Uman-health-formulations , Onsumer-wellness , Nimal-health-business

Zydus Cadila Q4 net up 73% to Rs 679 cr, total income up a marginal 3%

Zydus Cadila posted a 73 per cent surge in its net profit, year on year, to Rs 679 crore for the quarter ended March 31, 2021.
However, the company's total income from operations grew by just three per cent to Rs 3,847 crore, from Rs 3,752 crore during corresponding period of the previous year.
For the full year ended March 31, 2021, the company had a consolidated net profit of Rs 2,134 crore and total income from operations of Rs 15,102 crore.
Zydus Cadila's domestic business grew 18 per cent during the quarter to Rs 1,772 crore, with the human health formulations business growing by 15 per cent while the consumer wellness business grew by 22 per cent.

Zydus-cadila , Pegylated-interferon , ஜய்துச்-காடிலா ,

Drugmaker Zydus Cadila's fourth quarter net profit up 73% at Rs 679 crore

Pharmaceutical major Zydus Cadila said on Thursday its net profit jumped 73 per cent year-on-year to Rs 679 crore during the quarter ended March.
Earnings before interest, depreciation and tax (EBIDTA) grew by 8 per cent to Rs 855 crore in Q4 FY21, it said in a statement.
Total income from operations of Rs 3,847 crore was up by 3 per cent from Rs 3,752 crore in Q4 FY20.
The company's business in India geography which comprises human health formulations, consumer wellness and animal health business posted a growth of 18 per cent with revenues totalling Rs 1,772 crore.
US formulations business registered revenues of Rs 1,509 crore in Q4 FY21. Strengthening its regulatory pipeline, the company filed 22 additional abbreviated new drug applications (ANDAs) during the year with US Food and Drug Administration, taking the cumulative filings to 412.

India , Zydus-cadila , Drug-administration , Pegylated-interferon , இந்தியா , ஜய்துச்-காடிலா ,

Zydus Cadila's EBIDTA crosses mark of Rs. 30 bn

Zydus Cadila's EBIDTA crosses mark of Rs. 30 bn
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Boston , Massachusetts , United-states , India , American , Zydus-cadila , American-association , Time-zone , Total-income , Net-profit , Pegylated-interferon , Chronic-kidney-disease

Zydus's `Virafin' gets emergency use approval from DGCI for treatment of Covid patients

Industry > Industry monitor > Pharmaceuticals
23 April 2021
The Drug Controller General of India (DCGI) has granted Restricted Emergency Use Approval for Zydus Cadila’s Pegylated Interferon alpha-2b (PegIFN) or `Virafin’ for treating moderate Covid-19 infection in adults.
A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications, the company stated in a release.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating Covid-19. The drug has also shown efficacy against other viral infections.

India , Zydus-virafin , Sharvil-patel , Biotechnology-industry-research-assistance-council , Cadila-healthcare , Department-of-biotechnology , Drug-controller-general , Restricted-emergency-use-approval , Zydus-cadila , Pegylated-interferon , Cadila-healthcare-limited , Interferon-alpha

Zydus announces prices for its Covid drug Virafin approved by DCGI for use in moderate cases

Zydus announces prices for its Covid drug Virafin approved by DCGI for use in moderate cases
Zydus announces prices for its Covid drug Virafin approved by DCGI for use in moderate cases
Zydus Cadila on Tuesday announced the market price of Virafin, its drug that has been granted emergency use approval by the DCGI for the treatment of moderate cases of Covid-19.
advertisement
Zydus Cadila Covid-19 vaccine Virafin has begun dispatching doses to its vendors (Picture Credits: PTI)
Drug Firm Zydus Cadila has set the price of its medicine ‘Virafin' at Rs 11,995 per dose. After the DCGI's approval for use of this medicine in the treatment of moderate cases of Covid-19, the pharma giant has begun dispatching doses to its vendors.

India , Zydus-cadila , Drug-firm-zydus-cadila , Drug-controller-general , Pegylated-interferon , இந்தியா , ஜய்துச்-காடிலா , மருந்து-கட்டுப்படுத்தி-ஜநரல் ,

Natco Pharma seeks approval for phase-3 trial of antiviral drug Molnupiravir for COVID-19 treatment

Natco Pharma seeks approval for phase-3 trial of antiviral drug Molnupiravir for COVID-19 treatment
As per a press release from the Hyderabad-based company, pre-clinical data has proven that Molnupiravir has broad anti-influenza activity, comprising highly potent inhibition of SARS-CoV-2 replication
BusinessToday.In | April 26, 2021 | Updated 12:30 IST
Hyderabad-based drugmaker Natco Pharma is ready to launch the product this month if approval is given
Drugmaker Natco Pharma Limited said on Monday that it has applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of phase-3 clinical trial of coronavirus antiviral drug Molnupiravir Capsules for the treatment of COVID-19 patients.
The capsule has been developed by US pharma major Merck along with Ridgeback Biotherapeutics. As per a press release from the Hyderabad-based company, pre-clinical data has proven that Molnupiravir has broad anti-influenza activity, comprising highly potent inhibition of SARS-CoV-2 replication.

Hyderabad , Andhra-pradesh , India , Ridgeback-biotherapeutics , Zydus-cadila , Natco-pharma , Drugmaker-natco-pharma , Central-drugs-standard-control-organisation , Drugmaker-natco-pharma-limited , Molnupiravir-capsules , Drugs-controller-general , Pegylated-interferon

Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug

Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, according to a press release from Natco
BusinessToday.In | April 26, 2021 | Updated 16:17 IST
NATCO is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients
The share price of Natco Pharma rose over 7 per cent today after the company announced that it has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.

India , Zydus-cadila , Natco-pharma , Central-drugs-standard-control-organization , Molnupiravir-capsules , Drugs-controller-general , Pegylated-interferon , இந்தியா , ஜய்துச்-காடிலா , நாட்கோ-பார்மா , மைய-மருந்துகள்-தரநிலை-கட்டுப்பாடு-ஆர்கநைஸேஶந் , மருந்துகள்-கட்டுப்படுத்தி-ஜநரல்